pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Neurology · news · pharmadog
← back to Neurology
News · Neurology
268
stories
2d
Foghorn cuts 40% of workforce
biospace
2d
Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen
biospace
4d
FDA Launches Nationwide Effort to Expand Scientific Expertise and Consumer Voices to Advisory Committees
fda press
4d
Opinion: STAT+: What to think about those mice with half-human brains
stat
6d
An ‘off-the-shelf’ CAR-T therapy from Adicet shows promise against lupus
biopharma dive
6d
STAT+: AbbVie wins FDA nod for Parkinson’s pill
stat
6d
Regenerative medicine needs more than stem cells
biospace
6d
Milestone Sanfilippo nod helps Ultragenyx regroup after tough Angelman defeat
biospace
8d
AbbVie's next-gen dopamine therapy for Parkinson's gets FDA approval
endpoints
10d
RNAi drug specialist ADARx raises $446M IPO
biopharma dive
10d
Kyverna steps closer to FDA-first CAR T for an autoimmune condition with durability data
biospace
11d
Immunovant ditches lupus for multi-hyphenate inflammatory drug after mid-stage miss
biospace
11d
Roche-Ionis’ RNA therapy reduces kidney disease marker, opening path to swift FDA nod
biospace
11d
Ionis-Otsuka offer 'groundbreaking' improvement in function and survival for genetic type of ALS
biospace
11d
Opinion: Mentally ill women deserve more support to have children
stat
12d
2026 IPO blitz continues with 4 new biotech filings
biospace
12d
An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
biopharma dive
12d
Boehringer Ingelheim bets up to $1B in AI-centered solid tumor collab with Envisagenics
biospace
12d
New federal autism committee head has financial ties to leucovorin
stat
12d
Lexeo takes up the Mantle in $8M acquisition for Friedreich ataxia assets
fiercebiotech
13d
Global Mix Inc. Recalls Niwali Tejocote Capsules and Niwali Tejocote Pieces Because of Possible Health Risk
fda recalls
13d
Boehringer, Envisagenics sign $1B multi-target oncology collaboration
fiercebiotech
13d
Mikhail, Davis on board with regulatory framework tailored to rare disease therapies
biospace
16d
Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug
biopharma dive
16d
Xenon tumbles on voluntary psychiatry hold, but analysts confident in $2B epilepsy opportunity
biospace
16d
With pioneering ADHD data, Alkermes eyes orexin agonist as potential ‘company changer’
fiercebiotech
16d
Ultragenyx wins FDA greenlight for first Sanfilippo therapy, priced at nearly $4M
biospace
17d
Chutes & Ladders—Legend poaches Novartis vet to boost commercial potential
fiercebiotech
17d
STAT+: New startup to test psychedelic-like drug against Parkinson’s symptom
stat
17d
Purer fentanyl won’t solve the U.S. overdose death crisis, study says
stat
← prev
page 1 of 9
next →
